Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine-gynecology disorder affecting many women of childbearing age. Although a part of the involved mechanism in PCOS occurrence is discovered, the exact etiology and pathophysiology are not comprehensively understood yet. We searched PubMed for PCOS pathogenesis and management in this article and ClinicalTrials.gov for information on repurposed medications. All responsible factors behind PCOS were thoroughly evaluated. Furthermore, the complete information on PCOS commonly prescribed and repurposed medications is summarized through tables. Epigenetics, environmental toxicants, stress, diet as external factors, insulin resistance, hyperandrogenism, inflammation, oxidative stress, and obesity as internal factors were investigated. Lifestyle modifications and complementary and alternative medicines are preferred first-line therapy in many cases. Medications, including 3-hydroxy-3-methyl-3-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, glucose-like peptide-1 receptor agonists, mucolytic agents, and some supplements have supporting data for being repurposed in PCOS. Since there are few completed clinical trials with a low population and mostly without results on PCOS repurposed medications, it would be helpful to do further research and run well-designed clinical trials on this subject. Moreover, understanding more about PCOS would be beneficial to find new medications implying the effect via the novel discovered routes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperandrogenism, hyperinsulinism and insulin resistance (IR) are the main drivers of clinical, metabolic and reproductive phenotypes of PCOS.”
From Low-Calorie Ketogenic Diet: Potential Application in the Treatment of Polycystic Ovary Syndrome in Adolescents (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, the DAI has been developed as a more specific measure of adipose tissue dysfunction by combining WC, BMI, TG levels, and HDL-C [9,10,11].”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The VAI is an established marker of abdominal obesity and IR, integrating WC, triglyceride (TG) levels, and high-density lipoprotein cholesterol (HDL-C) to predict metabolic risk.”
From Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083 · cited 3×
“In addition, it should be mentioned that studies on PCOS women approved the resemblance of their fatty tissue to men, and hence the effect of HA on adipose tissue dysfunction [8].”
BackgroundInfluentialRosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603 · cited 9×
“Hyperinsulinemia increases LH-binding sites and androgen-producing response to LH [44].”
BackgroundInfluentialChronic Low Grade Inflammation in Pathogenesis of PCOS
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A. M., Smolarczyk, R., & Meczekalski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073789 · Cited by 680
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557 · cited 1×
“One way androgen results in oxidative stress is by increasing MNC sensitivity to glucose and aggravating glucosestimulated oxidative stress [65].”
BackgroundPolycystic Ovarian Syndrome: Correlation Between Hyperandrogenism, Insulin Resistance and Obesity.
Zeng, X., Xie, Y.-J., Liu, Y.-T., Long, S.-L., & Mo, Z.-C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.003 · Cited by 525 · cited 9×
“It also plays a role in progesterone and estrogen production, ovulation, and decreased GnRH secretion [52].”
BackgroundInfluentialA novel and compact review on the role of oxidative stress in female reproduction
Lu, J., Wang, Z., Cao, J., Chen, Y., & Dong, Y. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0391-5 · Cited by 481 · cited 11×
“Taking SFAs induces inflammation by triggering an increase in TNF-α level in circulation and expressing a specific cytokine suppressor [36].”
BackgroundInfluentialIbáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463 · cited 7×
“This receptor hypomethylation leads to higher gene expression and sensitivity to LH [18,20].”
BackgroundInfluentialCharacteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442 · cited 3×
“Excess abdominal fat is also responsible for the inflammatory condition [6,44,81].”
BackgroundCassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016) · Human Reproduction · doi:10.1093/humrep/dew243 · Cited by 415 · cited 1×
“On the other hand, hyperinsulinemia reduces hepatic SHBG [18,32,40,49,52,54–56], increasing free testosterone levels in blood [18,32,52,54,56].”
Background
Research works printed but not linked: 3
- Casadesús J. Noyer-Weidner M. Epigenetics Brenner’s Encyclopedia of Genetics 2nd ed. Maloy S. Hughes K. Academic Press San Diego, CA, USA 2013 500 503
- Jones L. Regan F. Endocrine Disrupting Chemicals Encyclopedia of Analytical Science 3rd ed. Worsfold P. Poole C. Townshend A. Miró M. Academic Press Oxford, UK 2019 31 38
- Zeind C.S. Carvalho M.G. Applied Therapeutics: The Clinical Use of Drugs Wolters Kluwer Health Philadelphia, PA, USA 2017
Cited by
Items 101–200 of 497
The Application of Complementary and Alternative Medicine in Polycystic Ovary Syndrome Infertility
Shi, Y.-Q., Wang, Y., Zhu, X.-T., Yin, R.-Y., Ma, Y., Han, H., Han, Y., & Zhang, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5076306 · Cited by 11
“Overexpression of proinflammatory factors and intense oxidative stress (OS) in PCOS patients inhibits follicle stimulating hormone (FSH) and luteinizing hormone (LH) receptor expression, leading to oocyte dysplasia and eventually infertility [8, 9].”
BackgroundZhou, Y., Wang, X., Guo, S., Li, R., Li, Y., Yu, Y., & Liu, T. H. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2302402 · Cited by 14
Fawzi, H. A., Hamad, I. N., Kadhim, S. A. A., AL-Temimi, S. M., Mohammad, B. I., & Swadi, A. A. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2023-0317 · Cited by 16
Panchpuri, M., Kisku, A., Painuli, R., Pant, G., & Kumar, C. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02117-5 · Cited by 13
“Considering the long-term risks, including a two-to fourfold increase in ovarian cancer in women treated with gonadotropins, clinicians should always aim for a singleton pregnancy, especially in patients with PCOS (Sadeghi et al. 2022).”
Simaei, S. R., Askari, V. R., Rostami, M., Kamalinejad, M., Farzaei, M. H., Morovati, M. R., Heydarpour, F., Jafari, Z., & Rahimi, V. B. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105720 · Cited by 10
Huang, H. Y. R., Badar, S. M., Said, M. T., Shah, S., Bharadwaj, H. R., Ramamoorthy, K., Alrawashdeh, M. M., Haroon, F., Basit, J., Saeed, S., et al. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09457-x · Cited by 11
“While the exact mechanism behind PCOS occurrence has not been determined, an excess ratio of luteinizing hormone to follicle-stimulating hormone, along with increased levels of gonadotropin-releasing hormone is known to contribute to PCOS onset [138].”
Varshney, K. K., Gupta, J. K., & Srivastava, R. (2024) · Protein and Peptide Letters · doi:10.2174/0109298665294109240323033601 · Cited by 10
Roy, M., Parveen, R., Khan, P. M., Majid, H., Pathak, M., Saxena, R. K., & Agarwal, N. B. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2407513 · Cited by 11
“However, there are various limitations of conventional medications such as combined oral contraceptives may lead to adverse events such as migraine, depression, headache, nausea, and vomiting [8,9].”
Long-term and low-dose exposure to triclosan induces POI phenotype in female offspring mice
Gan, H., Jiang, Y., Wu, L., Zhu, B., Ji, D., Liu, J., Ding, Z., & Ye, X. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.125966 · Cited by 11
Adipose tissue and androgens: the ins and outs
Jia, Y., Lacombe, M., Muller, C., & Milhas, D. (2025) · Adipocyte · doi:10.1080/21623945.2025.2508885 · Cited by 12
“It is frequently associated with obesity [10].”
Ranneh, Y., Hamsho, M., Shkorfu, W., Terzi, M., & Fadel, A. (2025) · Nutrients · doi:10.3390/nu17152436 · Cited by 11
“Development of PCOS can lead to T2DM and CVD which underscores the importance of early treatment [38,39].”
Govindharajan, G., Subramanian, S., Doraipandian, M., & Rajendran, S. (2025) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-025-10358-w · Cited by 16
Yao, B., Yu, X., Zhang, Y., Chen, J., Zhu, X., Zhang, C., & Jijun, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1719631 · Cited by 11
Association of polycystic ovary syndrome with multiple health factors and adverse pregnancy outcomes
Markin, L. B., Коrytko, О. О., Fartushok, T. V., Fartushok, N. V., Fedevych, Y. M., Dzhalilova, E. A., & Zhykovskiy, V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.2.2023.1259 · Cited by 14
Chen, L., Liu, Y., Zhang, L., Li, J., Xiong, W.-Q., Li, T., Ding, H., & Li, B. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1294339 · Cited by 16
“Consequently, ovulation induction is the most crucial treatment option for infertile patients with PCOS, despite various therapeutic medications have varying ovulation induction effects (7).”
BackgroundHu, R., Long, S.-L., Luo, M., Tang, B., Tan, T., Dong, W., Wang, Q., & Zhang, J. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300915 · Cited by 11
Tzeravini, E., Tentolouris, A., Kokkinos, A. D., Tentolouris, N., & Katsilambros, N. L. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100291 · Cited by 12
“Insulin resistance plays a pivotal role in the pathogenesis of polycystic ovary syndrome (PCOS) [115].”
Nanoparticles in Hormonal Regulation of the Female Reproductive System
Vijayakumar, V., Rathinam, T., Deenadhayalan, S. S., Edwin, E. R., Harikrishnan, P., & Balaji, P. (2024) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0027 · Cited by 14
Liu, D., Liu, D., & Zhou, K. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01617-2 · Cited by 11
“Additionally, PCOS increases the risk of several complications, including endometrial cancer, pregnancy complications (e.g., gestational diabetes and preeclampsia), cardiovascular diseases, type 2 diabetes mellitus, metabolic syndrome, depression, and anxiety [5].”
Hippo signaling pathway in polycystic ovary syndrome
Wen, J., Cheng, G., Zhang, Y., & Liu, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1623143 · Cited by 10
“Notably, current therapeutic interventions remain challenging, with patients facing signi fi cant risks of comorbidities such as type 2 diabetes mellitus, cardiovascular disease and non-alcoholic fatty liver disease (2).”
Gut microbiome dysbiosis in PCOS: from pathogenesis to microbiome-targeted therapies
Du, X., Su, H., Huang, Y., Liu, J., Li, Q., Yang, X., Tao, X., & Li, R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1747766 · Cited by 12
“Early diagnosis and targeted interventions, addressing both reproductive and metabolic aspects, are crucial in mitigating long-term complications (6).”
Chao Nang Qing prescription promotes granulosa cell apoptosis and autophagy by targeting GATA3
Luo, L., Shen, Y., Ning, D., Tang, M., Xie, L., Zheng, Q., & Ouyang, Z. (2023) · Gynecological Endocrinology · doi:10.1080/09513590.2023.2223724 · Cited by 9
Lu, F.-F., Wang, Z., Yang, Q., Yan, F.-S., Xu, C., Wang, M.-T., Xu, Z.-J., Cai, S.-Y., & Guan, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1438079 · Cited by 11
Wu, P.-Y., Tan, X., Wang, M., Zheng, X., & Lou, J.-H. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2118709 · Cited by 9
Kallistatin as a Potential Biomarker in Polycystic Ovary Syndrome: A Prospective Cohort Study
Yurtkal, A., & Canday, M. (2024) · Diagnostics · doi:10.3390/diagnostics14141553 · Cited by 9
Michenzi, C., Myers, S. H., & Chiarotto, I. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401037 · Cited by 8
Liu, D., Wei, C., Guan, L., Ju, W., Shan, X., & Lian, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1451300 · Cited by 10
Ghrelin–LEAP2 interactions along the stomach–liver axis
Sakai, K., Nakazato, Y., Shiimura, Y., Zhang, W., & Nakazato, M. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0543 · Cited by 8
Özdemir, M., Mümüşoğlu, S., & Bilgiç, P. (2025) · Reproductive Sciences · doi:10.1007/s43032-025-01808-8 · Cited by 10
“Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder, affecting of reproductive-aged woman, with a prevalence ranging from 10–13% [1, 2].”
Comparing the metabolomic landscape of polycystic ovary syndrome within urban and rural environments
Patel, J. K., Chaudhary, H., Chudasama, A., Panchal, J., Trivedi, A., Panchal, S., Joshi, T., & Joshi, R. G. (2025) · Communications Medicine · doi:10.1038/s43856-025-00985-6 · Cited by 9
“The prevalence of disorders and manifestations vary signi fi cantly between dif-ferentgeographicallocations,in fl uencedbydistinctenvironmental,lifestyle, and dietary factors 14 .”
Zhu, Y., Luo, D., Shen, X., Shi, Q., Lv, H., Zhang, S., Ye, F., & Kong, N. (2025) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-025-03114-4 · Cited by 10
“…of this study include: (1) the sample size ( n = 85) is relatively small considering the high prevalence and phenotypic heterogeneity of PCOS [24, 25]; (2) the sample mainly originated from a single tertiary hospital, which may introduce selection bias [12]; (3) some metabolic and endocrine…”
Alnaeem, L., Alnasser, M. N., AlAli, Y. A., Almarri, F., Sultan, A. A. A., Almuhaysin, F. A., Boubshait, N., & Almulhim, L. A. A. (2024) · Cureus · doi:10.7759/cureus.51530 · Cited by 15
“PCOS also causes hyperandrogenism, leading to a higher concentration of testosterone [5].”
BackgroundShen, J.-Y., Xu, L., Ding, Y., & Wu, X.-Y. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i23.5468 · Cited by 7
Gökçek, İ., Uyanık, G., Tutar, T., & Gözer, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03588-5 · Cited by 8
“Pharmacological treatment of PCOS includes interventions such as oral contraceptive pills, and hormone therapy (Patel 2018; Sadeghi et al. 2022).”
ZhaoWei, C., Zhang, R., Liu, R., Zhao, L., & Zhou, L. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01700-8 · Cited by 9
“Polycystic Ovary Syndrome (PCOS) is the most common endocrine-metabolic disorder in women of reproductive age, affecting approximately 5% to 10% of women [1].”
Li, B., Zha, Y., Deng, M., Niu, L., Li, X. L., Zhu, R., Tian, J., & Lu, J. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01982-5 · Cited by 8
“…age of 20 [2], marital status is missing [3], poverty income ratio is missing [4], body mass index is missing [5], waist circumference is missing [6], blood lipids is missing [7], fasting plasma glucose is missing [8], fasting insulin is missing [9], alcohol use is missing [10], cigarette use is…”
Kwiatkowski, J., Akpang, N., Zaborowska, Ł., & Ludwin, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157525 · Cited by 10
“Although PCOS was first described by Stein and Leventhal in 1935, its exact pathogenesis remains unclear, resulting in a lack of targeted pharmacological interventions [9,10].”
Polycystic ovary syndrome and organochlorine pesticides: exploring potential links and mechanisms
Yin, S., Yang, W., Lin, F., Jia, M., Feng, Y., Chen, Y., Bai, X., Dong, Y., Mao, S., Hayat, K., et al. (2025) · Frontiers in Reproductive Health · doi:10.3389/frph.2025.1563414 · Cited by 7
“From a genetic perspective, the disorder may arise from cumulative effects of polymorphisms in genes related to steroidogenesis, insulin signaling, and chronic in fl ammation, alongside epigenetic modi fi cations and altered protein pro fi les that collectively drive systemic dysfunction (39, 40).”
Polycystic Ovary Syndrome and the Effects of a Ketogenic Diet: A Scoping Review
Fleigle, D., Brumitt, J., McCarthy, E., Adelman, T., & Asbell, C. (2025) · Nutrients · doi:10.3390/nu17172893 · Cited by 9
“An example of an epigenetic change includes LH/choriogonadotropin receptor hypomethylation, which leads to increased LH levels [4].”
InfluentialChen, W., Xu, D., Shao, X., Song, Q., & Chen, R. (2025) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2553052 · Cited by 9
“GLP-1 RA cannot only improve blood glucose by activating the GLP-1 receptor, but also reduce body weight by suppressing appetite, delaying gastric emptying, and increasing energy expenditure [11].”
Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets
Shirasath, K. R., Ahmed, N. Z., Kumar, P., Alam, S., Karwasra, R., Goyal, S. N., & Agrawal, Y. O. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156245 · Cited by 7
He, J., Liu, A., Shen, H., Jiang, Y., Gao, M., Yu, L., Du, W., Zhang, X., & Fu, F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1335106 · Cited by 8
“…affects the reproductive health of women of childbearing age, PCOS is affected by a variety of external factors (epigenetics, environmental toxins, physical and emotional stress, diet) and internal factors (insulin resistance, androgen excess, in fl ammation, oxidative stress, obesity) (32, 33).”
BackgroundZheng, X., Zhao, D., Liu, Y., Jin, Y., Liu, T., Li, H., & Liu, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115739 · Cited by 7
Qi, J., Han, H., Li, X., & Ren, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296455 · Cited by 9
Bulu, A., Önalan, E., Yakar, B., Bulu, G., Yıldırım, S. O., Uğur, K., & Dönder, E. (2025) · Medicina · doi:10.3390/medicina61061012 · Cited by 8
“Despite all these treatments and pathophysiological processes, no definitive drug or definitive treatment has been approved for PCOS [8].”
Karimzadeh, H., Aghaei, R., Jourabchi, A., Shoorei, H., & Abdi, M. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2540853 · Cited by 6
“As a result, these alterations result in anovulatory cycles and a rise in unde-veloped follicles, both of which result in infertility [82]. the pathophysiology of PcOS is complex and shaped by various genetic, environmental, and hormonal influences.”
Kolasseri, A. E., Tamizhselvi, R., & Jayanthi, S. (2025) · Current Genomics · doi:10.2174/0113892029401274251009070350 · Cited by 6
“Reduced methylation of the gene epoxide hydrolase 1 enzyme suppresses testosterone and increases the risk of PCOS [33].”
Recent advances in therapeutic interventions of polycystic ovarian syndrome
Lad, S. U., Vyas, G., Mohd, S., Mishra, V. K., Wadhwa, S., Singh, S., & Harish, V. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100543 · Cited by 6
Deng, Y.-P., Zhou, Y.-L., Wei, T.-T., He, G.-S., Zhu, Z., Zhang, S.-N., Liu, M., Xue, J.-J., Zhang, W., & Yang, X. (2024) · Medicine · doi:10.1097/md.0000000000038912 · Cited by 9
“[2–5] Infertility due to PCOS accounts for approximately 30% of all female infertility cases and is the leading cause of anovulatory infertility.”
BackgroundHofmann, K., Oehler, M., Ruckes, C., Dionysopoulou, A., Stewen, K., Schiestl, L. J., Degirmenci, Y., Theis, S., Skala, C., Hasenburg, A., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40431 · Cited by 5
Mrabet, H. E., Salem, H. B., Ach, T., Abdelkarim, A. B., & Alaya, W. (2024) · SAGE Open Medicine · doi:10.1177/20503121241308997 · Cited by 8
Carriero, V. C., Forte, G., Dinicola, S., Oliva, M. M., Mudarris, G. A., & Unfer, V. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.113947 · Cited by 6
Effects of Low Vitamin C Intake on Fertility Parameters and Pregnancy Outcomes in Guinea Pigs
Coker, S. J., Dyson, R. M., Smith-Díaz, C. C., Vissers, M. C. M., & Berry, M. J. (2023) · Nutrients · doi:10.3390/nu15194107 · Cited by 7
“Among women of the child-bearing age, a leading cause of subfertility is polycystic ovarian syndrome (PCOS), a common endocrine disorder linked to disordered follicle development and diminished ovulation [57,58].”
BackgroundPolycystic ovary syndrome and adverse pregnancy outcomes: potential role of decidual function
Li, L., Ge, H., Zhou, J., Wang, J., & Wang, L. (2023) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2023.01096 · Cited by 9
Nizamani, M., Uddin, M. Z., Nagdev, C., Ahmed, N., & Raza, A. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.06.037 · Cited by 6
Abdessalem, F. B., Ach, T., Ghariani, N. F., Mraihi, E., & Abdelkarim, A. B. (2024) · Archives of Dermatological Research · doi:10.1007/s00403-024-03466-3 · Cited by 9
Tamaoka, S., Saito, K., Yoshida, T., Nakabayashi, K., Tatsumi, K., Kawamura, T., Matsuzaki, T., Matsubara, K., Ogata‐Kawata, H., Hata, K., et al. (2023) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12504 · Cited by 6
Genetic–epigenetic targets for PCOS-associated diabesity
Sharma, A. K., Mukherjee, M., Akhtar, M. S., Orayj, K. M., Farooqui, S., & Khan, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104373 · Cited by 5
Qu, J., Qiu, M., Wang, J., Chen, Z., Chen, M., Teng, X., & Li, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1626938 · Cited by 5
Luteolin alleviates PCOS by inhibiting AR/STAT3/NLRP3-mediated granulosa cell pyroptosis
Ouyang, X., Tang, H., Yang, Y., Hao, X., Jiang, X., Zhou, Q., & Li, L. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-025-01952-4 · Cited by 5
“Within its multifactorial etiology, hyperandrogenemia (HA) is recognized as a cornerstone of PCOS pathophysiology, driving follicular arrest and impairing ovarian function [4, 5].”
Zhang, L., Yin, C.-Q., Sun, S.-J., Teng, X.-Q., Li, D., Sun, J., & Cui, Y.-Y. (2023) · Medicine · doi:10.1097/md.0000000000035489 · Cited by 5
Zhao, J., Li, X., & Chen, Q. (2024) · Gene · doi:10.1016/j.gene.2024.148504 · Cited by 6
Hu, Z., Zeng, R., Tang, Y., Liao, Y., Li, T., & Qin, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1413068 · Cited by 8
“PCOS is now considered an endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovary morphology, affecting a great number of reproductive-aged women (8, 9).”
BackgroundBrain RFamide Neuropeptides in Stress-Related Psychopathologies
Kovács, A., Szabó, E., László, K., Kertes, E., Zagorácz, O., Mintál, K., Tóth, A., Gálosi, R., Berta, B., Lénárd, L., et al. (2024) · Cells · doi:10.3390/cells13131097 · Cited by 8
“For example, various types of stressors, including lipopolysaccharide-induced inflammation, acute restraint, or insulin-induced hypoglycemia, disrupted LH pulsatility, decreased KP expression or KP neuron activity, and altered Kiss1R mRNA expression in the HTH of female rodents [308,340,341].”
BackgroundZhang, Y., Cao, S., Liang, J.-X., Hu, S.-H., Guo, X.-F., Chun-jing, S., & Ge, L.-N. (2024) · Medicine · doi:10.1097/md.0000000000039030 · Cited by 5
Ren, M., Yang, T., Liu, M., Ma, X., Li, B., Al-Mughalles, A. S., Pei, X., & Zhang, S. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150634 · Cited by 6
Polycystic ovary syndrome: new and promising treatment methods
Муратовна, Г. Д., Sheremetyeva, E. V., Kalashnikova, M. F., Dzgoeva, F. K., & Алборова, Е. Т. (2024) · Problems of Endocrinology · doi:10.14341/probl13400 · Cited by 13
Natural Chemical Constituents and Polymer Used in to Reduce PCOS Pain
Sarwade, P. P., Dhanasree, B., Gaisamudre, K. N., Kumar, R., Banerjee, A., Dubey, S. A., Otia, M. K., & Kumar, V. (2025) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.4.1.10 · Cited by 5
Effects of melatonin in polycystic ovary syndrome: is there Hippo pathway crosstalk?
Wang, L., Jin, Y., Zhi, Y., Li, Z., Wang, M., Wang, B., & Wang, X. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01642-1 · Cited by 6
“Rather, it is associated with a complex interplay of intrinsic mechanisms, including genetic predispositions, environmental factors, and in utero influences [24].”
Du, M., & Ge, H. (2025) · Medicine · doi:10.1097/md.0000000000042481 · Cited by 5
“[1,2] Beyond its impact on fertility, PCOS is closely linked to various metabolic and endocrine disturbances.”
Actualización sobre síndrome de ovario poliquístico
Delgado, J. G., Saavedra, M. M., & Miranda, N. M. (2022) · Revista Medica Sinergia · doi:10.31434/rms.v7i5.801 · Cited by 5
Uma abordagem geral da Síndrome dos Ovários Policísticos: revisão de literatura
Cremonez, L. D. S. C., & de Siqueira, E. C. (2022) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e10908.2022 · Cited by 9
Ibrahim, Z. A. H., Abdulridha, M. K., & Razoqi, R. B. (2023) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v23i3.1045 · Cited by 5
Progress of the application clinical prediction model in polycystic ovary syndrome
Guan, G., Yifu, P., Yuan, G., Xialei, L., Shi, F., Sun, Q., Jinjin, X., Linna, Z., Xiaozuo, Z., Wen, F., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01310-2 · Cited by 7
“Overall, the definition of PCOS has become clearer [84, 85].”
BackgroundPerspectivas atuais sobre Síndrome dos Ovários Policísticos: abordagens diagnósticas e terapêuticas
Nobre, P. V. C., Júnior, J. D. A. A., Macena, L. B., da Rocha, M. S. M. V., Costa, K. E. N., Melo, T. R. B., Silva, L. S. R., Sampaio, M. T. C. N., Meneses, J. V. S., Cordeiro, K. I. C., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n3p2500-2510 · Cited by 7
Lin, J., Lin, H., Li, W., Huang, J., Chen, L., & Wang, R. (2024) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2024.2372695 · Cited by 6
“The pathogenesis of PCOS has not been fully elucidated, but related studies have shown that genetics, genetic changes, environmental factors, oxidative stress, chronic low-grade inflammation and other factors are involved in the occurrence of PCOS [4].”
Wang, J., Wang, Y., Li, S., Xiaoqin, F., Zhang, C., Wang, Z., Zheng, Y., Deng, H., Xu, S., & Mi, Y. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2427202 · Cited by 5
Zhang, Q., Ke, W., Ye, J., Zhang, P., Yang, Q., Pan, F., Wang, K., & Zha, B. (2024) · Endocrine · doi:10.1007/s12020-024-03756-w · Cited by 5
“Polycystic ovary syndrome (PCOS) is a kind of reproductive endocrine disorder, characterized by irregular menstrual cycles, hyperandrogenism and polycystic ovaries, affecting women since childbearing age [9].”
Younas, S., Bukhari, D. A., Bibi, Z., Ullah, A., & Rehman, A. (2025) · Applied Food Research · doi:10.1016/j.afres.2025.101054 · Cited by 4
Qasim, A., Calvo, H., Escobar, J. J. M., & Akhtar, Z.-U.-D. (2025) · Biology · doi:10.3390/biology14070903 · Cited by 4
Kugelman, N., Pooni, A., Rotshenker-Olshinka, K., Bellemare, V., Digby, A. M., & Dahan, M. H. (2024) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2024.2023-12-9 · Cited by 4
Variations in anterior segment parameters among different phenotypes of polycystic ovary syndrome
Sümer, F., Gürlek, B., Yıldız, E., Uzun, F., Aslan, M. G., Çolak, S., & Akgöz, H. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03676-3 · Cited by 4
“It is a diverse endocrine disorder characterized by irregular or absent menstrual periods, elevated androgen levels, and the presence of numerous small cystic follicles beneath the ovarian capsule, as identified through ultrasonography [2].”
BackgroundClinical significance and biological roles of lncRNA CTBP1-AS in polycystic ovary syndrome
Qin, L., Tian, C., Huang, L.-Y., Xiao, Q., Ling, S., Wei, J., Huang, B., Li, L., & Luo, X. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01571-5 · Cited by 4
Bai, Y., Chang, H., Tang, N., Zhou, H., Wang, X., Shen, K., Xu, Z., Du, Y., Zhang, X., Zhang, Q., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92006-8 · Cited by 4
Jin, Y., Hu, H., Zhang, J.-C., Zhu, Y., Zhang, H., Xin, X., Fan, R., Yang, Y., Li, Y., & Li, D. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01165-3 · Cited by 4
“…its reproductive implications, PCOS is strongly associated with systemic glucolipid metabolic dysregulation [8], including insulin resistance (IR) [9], dysfunctional adipose tissue plasticity [10], mitochondrial bioenergetic insufficiency, [11, 12] and the subsequent development of type 2…”
Comprehensive Overview of PCOS: Exploring Etiology, Diagnosis, and Treatment Approaches
Singh, S. K., Gori, P., Patel, P., & Paul, A. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00419-w · Cited by 5
Liu, M., Xiong, Y., Zhang, S., Yuan, J., & Cheng, Z. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s536122 · Cited by 4
Hua, R., Li, J.-J., Yang, W., Hua, Y., & Ma, Y.-L. (2025) · European journal of medical research · doi:10.1186/s40001-025-02910-y · Cited by 4
“Understanding this relationship could lead to more targeted treatment approaches, addressing not only the reproductive and metabolic symptoms of PCOS but also the underlying thyroid dysfunction [15, 16].”
Zhang, R., Wang, X., Mo, M., Liu, Z., & Su, L. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01453-5 · Cited by 6
“Recent studies have indicated that genetic predispositions, epigenetic alterations, environmental factors, oxidative stress, chronic low-grade inflammation, mitochondrial dysfunction, and metabolic disorders are involved in the aetiology of PCOS and thus affect normal ovarian function [3–6].”
Huang, R., & Gao, M. (2025) · Reproductive Sciences · doi:10.1007/s43032-025-01966-9 · Cited by 4
Chen, K., Geng, H., Zheng, Y., Xie, H., Qin, R., Chen, J., & Ye, C. (2025) · Advanced Science · doi:10.1002/advs.202506497 · Cited by 5
Mohanty, A., Bashir, B., Kolekar, K. A., Acharya, A., Gulati, M., Chaitanya, M., Gupta, M., Patle, D., Gupta, G., & Singh, S. K. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02015-2 · Cited by 4
“Hormonal medications help con-trol menstrual patterns together with reducing abnormal androgen levels thus treating both symptoms and biological sources (Sadeghi et al. 2022).”
Sharif, H., Arsalan, S., Rehman, N., Muzammil, A., Hatif, F., Wasti, F., Rehman, S., Mohsin, N., Nasir, R., & Omair, W. (2025) · BMC Women s Health · doi:10.1186/s12905-025-04091-6 · Cited by 6
“Type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, insulin resistance, oligo-ovulation or anovulation, hyperandrogenism, and ultrasound findings such as polycystic ovarian syndrome are among the metabolic and hormonal disorders that define it [15].”
Hu, X., Zhu, M., Zhou, Q., Li, Z., Luo, L., Liang, W., Chen, S., Pu, X., & Du, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s574929 · Cited by 5
“88 Hyperandrogenism further correlates with heightened oxidative stress and inflammatory markers, although the causal relationships among these abnormalities are still being defined.”
Clinical management of androgen excess and defect in women
Rosato, E., Sciarra, F., Minnetti, M., Degjoni, A., & Venneri, M. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2279537 · Cited by 4
“The most common hyperandrogenic disorder in reproductive age is PCOS [24], affecting 5–18% of women [25], with approximately an 80–85% prevalence among women with androgen excess [26–28].”
BackgroundLi, S., Ke, J., Cheng, J., Zhao, D., & Yu, K. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07273-7 · Cited by 4
“Previous clinical reports have shown that some PCOS symptoms were alleviated or even eliminated by restoring thyroid function [23], but whether other mechanisms are involved is still unclear.”
Wang, W., Tan, L., Ge, L., Gou, R., Gou, L., Liu, L., Zhang, L., & Ma, X. (2024) · Gynecologic and Obstetric Investigation · doi:10.1159/000540097 · Cited by 4
“…are several challenges remained for the diagnosis and management of PCOS owing to limited available diagnostic protocols and complex and multifactorial pathogenesis [8], while the management approach depends on the target patient and her priorities, being challenged by different complications [9].”
Alessandri, G., Mancabelli, L., Fontana, F., Lepore, E., Forte, G., Burratti, M., Ventura, M., & Turroni, F. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.14540 · Cited by 7
Jia, M.-J., Zhou, L., Liu, X.-N., & Li, H.-L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1433612 · Cited by 5
Complementary and alternative medicine therapies used by women with polycystic ovary syndrome
Elkoca, A., Özcan, H., & Yekeler, B. (2024) · Advances in Integrative Medicine · doi:10.1016/j.aimed.2024.12.004 · Cited by 4
Metadata
- Authors
- Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M.
- Affiliations
- Pharmaceutical Sciences Research Center (IR)
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
- University of Medicine and Pharmacy of Craiova (RO)
- Personalized Medicine Research Center (IR)
- University of Crete (GR)
- Corresponding author
- Abdollahi, Mohammad
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-01-06
- Volume
- 23
- Issue
- 2
- Pages
- 583
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8775814
- OpenAlex
- W4205636865
- Cited by
- 445
- References
- 106
- Citations by year
- 2026: 68 · 2025: 136 · 2024: 133 · 2023: 90 · 2022: 18
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, PCOS pathogenesis, drug repurposing, insulin resistance, hyperandrogenism, oxidative stress, inflammation, obesity, epigenetics, environmental toxins, stress, diet, statins, thiazolidinediones, SGLT2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, mucolytic agents, lifestyle modification, complementary and alternative medicine
- MeSH terms
- Female, Humans, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism, Disease Management, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.